Navigation Links
Clinical Update - Debio 0614 (Istaroxime) in Acute Heart Failure
Date:4/2/2008

LAUSANNE, Switzerland, and POMEZIA, Italy, April 2 /PRNewswire/ --

- Presentation of Phase IIa Efficacy Results

Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions, particularly oncology and cardiology, and sigma-tau Industrie Farmaceutiche Riunite SpA (sigma-tau), a leading Italian pharmaceutical group, today presented positive efficacy results of a phase IIa Horizon-HF study with Debio 0614 (formerly PST2744), also known as istaroxime, in development for the treatment of acute heart failure. Data showed that Debio 0614 is able to significantly reduce pulmonary congestion in patients admitted with worsening heart failure and left ventricular dysfunction. These findings were presented at the 57th American College of Cardiology (AAC) Annual Meeting in Chicago, by Mihai Gheorghiade, Professor of Medicine and Surgery at Northwestern University, Chicago and chair of the steering committee of the study.

The results of the study demonstrated that in patients with decompensated heart failure, Debio 0614 improves hemodynamics and diastolic function, without adversely affecting neurohormones or renal function. In this randomized, double-blind, placebo-controlled, multicenter trial, 120 patients were admitted with worsening heart failure, with a left ventricular ejection fraction below 35% and a pulmonary capillary wedge pressure above 20 mmHg. In 30 patients who received three doses of Debio 0614 over six hours, a statistically significant decrease of pulmonary wedge pressure (p<0.03 for all doses) was observed, with a reduction of the left ventricular diastolic volume (p=0.02 for the highest dose) and an increase in cardiac index (p=0.04 for the highest dose), compared to patients treated with placebo.

"Debio 0614 is a novel intravenous agent combining inotropic and lusitropic properties. Its innovative mechanism of action allows for improving systolic and dias
'/>"/>

SOURCE The Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Mast Therapeutics, Inc. (NYSE MKT: MSTX), a ... quarter ended September 30, 2014. Brian ... third quarter was productive for Mast. Consistent with prior guidance, ... sickle cell disease is on track to complete enrollment ... 50 study sites in the U.S. and more than ...
(Date:10/31/2014)... Today, Analysts Review released its ... ), Bristol-Myers Squibb Co. (NYSE: BMY ), ... SA (NYSE: SNY ) and Actavis plc ... of publication. To reserve complementary membership, limited openings are ... Research Reports ,On October 23, 2014, Celgene Corporation (Celgene) ...
(Date:10/31/2014)...  Encision Inc. (OTCQB:ECIA), a medical device company owning ... in minimally invasive surgery, today announced financial results for ... The Company posted quarterly net revenue of ... thousand, or $(0.04) per share. These results compare to ... of $50 thousand, or $(0.01) per share, in the ...
Breaking Medicine Technology:Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6Encision Reports Second Quarter Fiscal Year 2015 Results 2Encision Reports Second Quarter Fiscal Year 2015 Results 3Encision Reports Second Quarter Fiscal Year 2015 Results 4Encision Reports Second Quarter Fiscal Year 2015 Results 5
... ATLANTA, July 18, 2011 Among the many new features ... with a simple way to deliver highly conformal stereotactic plans ... a target as the treatment beam rotates around the patient. ... Food and Drug Administration. "DCA can be used ...
... Caliper Life Sciences, Inc. (NASDAQ: CALP ... life science companies, today announced that Kevin Hrusovsky, President ... Stock Market Opening Bell on Tuesday, July 19th and ... customers to participate in this special event. This event ...
Cached Medicine Technology:New Release of Elekta's Monaco Treatment Planning System Prepares Software for Stereotactic Radiation Therapy 2Caliper Life Sciences to Ring The NASDAQ Stock Market Opening Bell on Tuesday, July 19 2Caliper Life Sciences to Ring The NASDAQ Stock Market Opening Bell on Tuesday, July 19 3
(Date:10/31/2014)... Energy Textiles has recently added a ... is now available online, and Energy Textile is providing ... infrared-active athletic gear over compression gear. , The ... been signed for Under Armour to provide team gear ... years. In light of this decision, Energy Textiles contemplates ...
(Date:10/31/2014)... (HealthDay News) -- Sleep apnea may make it hard for ... your car or left your house keys, a small study ... showed that this ability -- called spatial memory -- was ... even when other stages of sleep weren,t affected. REM sleep ... occur. "We,ve shown for the first time that sleep ...
(Date:10/31/2014)... duration of treatment and cost, patients with early ... breast irradiation (APBI) with proton therapy versus whole ... The University of Texas MD Anderson Proton Therapy ... study based on typical patient characteristics, researchers used ... eight different types of partial and whole breast ...
(Date:10/31/2014)... out of four older Americans say that either they ... medical treatment, according to the latest issue of The ... Report ( PP&AR ), which goes on to ... they fail to honor patients, end-of-life health care wishes. ... Care: Issues and Options ," features 12 articles that ...
(Date:10/31/2014)... Gold Medal Wine Club is making ... gifts for the wine novice and enthusiasts on their lists ... Special , which Early Bird shoppers receive discounts as high ... membership. , Gift Givers must place their orders before ... discounts, Gold Medal Wine Club adds more value to its ...
Breaking Medicine News(10 mins):Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Advance directives can benefit patients, families, and health care system 2Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2
... especially when the pollen count is high in the atmosphere. ... every year. In almost 38 million people, congestion and post ... infections. Newer treatments are now availble to combat such an ... Head and Neck Surgeon at , of Methodist Dallas Medical ...
... shows thickening of the heart may put young people at ... heart muscle protein // and is noticeable after the growth ... of breath on exertion, and a family history of sudden ... hypertrophic cardiomyopathy, can be seen on an electrocardiogram, but formal ...
... that overweight women might want to shed those extra pounds ... to // have a false-positive finding on a routine mammogram. ... those of normal weight to get breast cancer and also ... study exists on the accuracy of mammograms in overweight and ...
... but new research shows postmenopausal women who exercise have ... cholesterol levels. ,For the study researchers included 50 ... medications and had no diseases that affect bone metabolism. ... week for 26 months as well as two at-home ...
... fibrillation run a higher risk of stroke than those ... causes blood to pool, which can lead to a ... A new test to monitor people for irregular heartbeats ... ,Investigators evaluated about 150 patients who had just suffered ...
... world’s second leading cause of blindness. More than 66 ... research suggests doctors need to do more than just ... glaucoma. Researchers say examination of the optic nerve ... not someone has early stage glaucoma. ,Researchers say ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: